UCSF

Tagged: breast cancer

Arkin receives Ono Pharma Foundation Breakthrough Science Initiative Award

Michelle Arkin, PhD, has received the 2018 Breakthrough Science Initiative Award from the Ono Pharma Foundation to study a class of proteins, called 14-3-3 proteins, known to be involved in various cancers, with the ultimate goal of enabling discoveries that lead to new ways to treat cancer.

Stopping cancer in its tracks

Cancer, fundamentally, is a problem of too much growth. For decades, health care providers have tried and failed to slow tumor growth using drugs that interfere with a particular signaling pathway, called PI3K, which is known to operate in proliferating cancer cells.

UC San Francisco establishes Quantitative Biosciences Institute

UC San Francisco today announced the establishment of the Quantitative Biosciences Institute (QBI). The mission of QBI, located in Byers Hall on the UCSF Mission Bay campus, is to drive forward the application of computation, mathematics, and statistics toward a deeper understanding of complex problems in biology, with the ultimate goal of developing new treatments for disease.

Kroetz leads new study of genetics of cancer drugs’ dose-limiting side effects

Taxanes are a class of drugs widely used to treat a variety of cancers, including breast, ovarian, lung, gastric, and head and neck. But dosages are often limited by toxic side effects—most commonly damage to the body’s peripheral nerves, causing numbness, pain, and/or hyper-sensitivity—that can require reduced or suspended treatment and which can linger for years in disease survivors.

Label warnings, antibiotic measurements, cancer therapies, and smoking interventions take top honors at annual seminar

Studies of improved over-the-counter acetaminophen warning labels, more accurate measurements of antibiotics in hospitalized patients, therapies for metastatic breast cancer, and methods for training pharmacy personnel to help smokers quit took top honors at the Department of Clinical Pharmacy’s 16th Annual Spring Research Seminar.

Gartner receives NIH New Innovator Award to build complex human breast tissue

Zev Gartner, PhD, has been named a recipient of the 2013 National Institutes of Health (NIH) Director’s New Innovator Award, which will provide his lab with up to $1.5 million in research funding over the next five years.

Study builds breast tissues to track how abnormal cells affect neighbors

It can take just the flick of a genetic switch for breast cells to kick-start the normally well-regulated process of growth seen in puberty, pregnancy, or the menstrual cycle—or the mutation of that switch to initiate the unchecked proliferation of cancer.

Gartner to lead study on the interactions of cells in breast cancer

Zev Gartner, PhD, a faculty member in the UCSF School of Pharmacy, will lead a US$3.2 million grant to study the interaction of different types of cells in breast cancer at its earliest stages. Research results might ultimately identify new classes of targets for anticancer drugs.

Study identifies lack of information about HER2 testing practices

Breast cancer patients might not be getting full advantage from a genetic screening test for the protein known as HER2 to help determine if the use of trastuzumab (marketed as Herceptin) is the best course of treatment for them. For patients whose breast cancer cells produce excessive amounts of HER2, trastuzumab can be highly effective.

Kroetz elected fellow of American Association of Pharmaceutical Scientists

Deanna Kroetz, PhD, UCSF School of Pharmacy faculty member, has been elected as a fellow of the American Association of Pharmaceutical Scientists (AAPS).